格隆汇11月13日丨康臣药业(01681.HK)公告，11月13日耗资3万港元回购2000股，每股回购价15港元。 ...

康臣药业(01681)发布公告，于2025年11月13日该公司斥资3万港元回购2000股，回购价格为每股15港 元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年11月11日 | | 847,983,407 | | 0 | | 847,983,407 | | 1). 其他 (請註明) | | | | % | | | | | 見B部分 | | | ...

Core Insights - On November 11, two Hong Kong stocks, Kangchen Pharmaceutical and Baihong Industrial, conducted share buybacks amounting to HKD 2.9692 million and HKD 0.0465 million respectively [1] - As of November 11, a total of 244 Hong Kong stocks have executed buybacks this year, with 58 stocks having repurchased over HKD 100 million [1] - Tencent Holdings, HSBC Holdings, and AIA Group have the largest cumulative buyback amounts this year, totaling HKD 60.965 billion, HKD 30.257 billion, and HKD 17.693 billion respectively [1]

Group 1 - Company announced a share buyback of 200,000 shares at a cost of HKD 2.97 million on November 11 [1]

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of shares [1] Summary by Category Company Actions - 康臣药业 plans to repurchase 200,000 shares at a cost of approximately HKD 2.9692 million on November 11, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Company Summary - 康臣药业 plans to repurchase 505,000 shares at a total cost of HKD 7.4928 million [1]

Core Viewpoint - 康臣药业 announced a share buyback of 505,000 shares at a cost of HKD 7.5 million on November 7 [1] Group 1 - The company spent HKD 7.5 million for the repurchase [1] - A total of 505,000 shares were bought back [1]

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1 - 康臣药业 plans to repurchase 505,000 shares at a total cost of HKD 7.4928 million [1] - The buyback is scheduled for November 7, 2025, reflecting the company's strategic approach to enhance shareholder value [1]